★ WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES ★
VOL. XCIV, NO. 247
Stock Profile
Coloplast A/S (COLOB) Moat Analysis
Coloplast A/S
COLOB · Nasdaq Copenhagen
Partial score covering 76% of segment weight.
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Request update
Spot something outdated? Send a quick note and source so we can refresh this profile.
Overview
Coloplast A/S is a Danish medical-device company focused on chronic and intimate healthcare. Its five H1 2025/26 business-area revenue shares sum to 100%. The strongest moats are in Ostomy and Continence Care, where frequently replenished disposables, product fit, patient routines and clinically sensitive trust support market-leading shares of 35-40% and 40-45%. Voice & Respiratory Care adds therapy training and an approximately 85% laryngectomy position. Wound & Tissue Repair has no current moat score: Kerecis recorded 0% organic growth, a 0% pre-PPA EBIT margin and a DKK 3.0bn goodwill impairment after Medicare reimbursement disruption. Interventional Urology also has no separately proven moat; its 15% share and support program do not demonstrate qualification lock-in or a hard-to-replicate service network. The June 2026 FDA approval of a next-generation inflatable penile prosthesis is a product catalyst, not moat evidence by itself.
Primary segment
Ostomy Care
Market structure
Oligopoly
Market share
35%-40% (reported)
HHI: —
Coverage
5 segments · 9 tags
Updated 2026-07-11
Segments
Ostomy Care
Ostomy care products (bags, plates, supporting products)
Revenue
35.5%
Structure
Oligopoly
Pricing
moderate
Share
35%-40% (reported)
Peers
Continence Care
Continence care products (intermittent catheters, collecting devices, bowel care)
Revenue
32.5%
Structure
Oligopoly
Pricing
moderate
Share
40%-45% (reported)
Peers
Voice & Respiratory Care
Laryngectomy and tracheostomy care products (voice prostheses, HMEs, adhesives, tubes)
Revenue
8.4%
Structure
Oligopoly
Pricing
moderate
Share
28%-41% (implied)
Peers
Wound & Tissue Repair
Advanced wound dressings and biologics/skin substitutes for wound care
Revenue
13.4%
Structure
Competitive
Pricing
weak
Share
5%-10% (reported)
Peers
Interventional Urology
Interventional urology products (Kidney & Bladder Health, Men's Health, Women's Health, endourology)
Revenue
10.3%
Structure
Oligopoly
Pricing
moderate
Share
14%-16% (reported)
Peers
Moat Claims
Ostomy Care
Ostomy care products (bags, plates, supporting products)
Revenue share computed from H1 2025/26 revenue by business area: Ostomy Care DKK 5,010m of total DKK 14,127m. The latest market-share evidence remains the FY 2024/25 release.
Installed Base Consumables
Demand
Installed Base Consumables
Strength
Durability
Confidence
Evidence
Core ostomy products are disposable and replenished frequently; once users find a good fit, repeat purchasing becomes sticky.
Installed Base Consumables moat: definition, examples, and stocks
Erosion risks
- Tender-driven switching
- Reimbursement price pressure
- Competitor product innovation
Leading indicators
- Market share trend
- Price/mix vs volume growth
- Tender win/loss cadence
Counterarguments
- Some payers force periodic re-tendering, reducing stickiness
- Patients can trial and switch brands with clinician support
Brand Trust
Demand
Brand Trust
Strength
Durability
Confidence
Evidence
High global share suggests durable trust among patients and clinicians in fit, comfort and skin performance.
Brand Trust moat: definition, examples, and stocks
Erosion risks
- Brand damage from quality issues
- Spec/feature parity narrowing differentiation
- Local low-cost competitors in tenders
Leading indicators
- Patient satisfaction / complaint rates
- Churn to competitors
- Gross margin in Ostomy category
Counterarguments
- Market leadership can be competed away via aggressive tender pricing
- Differentiation is incremental and can be copied
Continence Care
Continence care products (intermittent catheters, collecting devices, bowel care)
Revenue share computed from H1 2025/26 revenue by business area: Continence Care DKK 4,588m of total DKK 14,127m. The latest market-share evidence remains the FY 2024/25 release.
Installed Base Consumables
Demand
Installed Base Consumables
Strength
Durability
Confidence
Evidence
Intermittent catheters are typically single-use/high-frequency products; routines and reimbursement channels support recurring demand.
Installed Base Consumables moat: definition, examples, and stocks
Erosion risks
- Payer substitution to lower-cost catheters
- New entrants with similar coatings/features
- Reimbursement cuts
Leading indicators
- Intermittent catheter share trend
- Tender outcomes in key countries
- Unit economics (ASP vs volume)
Counterarguments
- Switching can occur quickly when payers change formularies
- Clinical differentiation may narrow over time
Brand Trust
Demand
Brand Trust
Strength
Durability
Confidence
Evidence
Large global share supports brand trust with clinicians/users around safety, comfort and innovation in catheter design.
Brand Trust moat: definition, examples, and stocks
Erosion risks
- Adverse events/quality issues harming trust
- Feature parity from competitors
- Tender-driven price compression
Leading indicators
- Market share and growth vs market
- Complaint/return rates
- Gross margin trend
Counterarguments
- Share leadership can be challenged by aggressive pricing and tender capture
- Users may multi-home or switch based on reimbursement
Voice & Respiratory Care
Laryngectomy and tracheostomy care products (voice prostheses, HMEs, adhesives, tubes)
Revenue share computed from H1 2025/26 revenue by business area: Voice & Respiratory Care DKK 1,181m of total DKK 14,127m. The latest market-share evidence remains the FY 2024/25 release.
Training Org Change Costs
Demand
Training Org Change Costs
Strength
Durability
Confidence
Evidence
Therapy regimes and device handling are clinician-influenced; patient routines and clinician training create friction to switch platforms.
Training Org Change Costs moat: definition, examples, and stocks
Erosion risks
- Competitors improve ease-of-use and compatibility
- Standardization of supplies via tenders
- Regulatory constraints on device claims
Leading indicators
- Share in laryngectomy and tracheostomy
- Clinic adoption / reorder rates
- Patient churn to competitor systems
Counterarguments
- If procurement is centralized, switching can be mandated despite training
- Some consumables are interoperable across systems
Brand Trust
Demand
Brand Trust
Strength
Durability
Confidence
Evidence
Dominant share in laryngectomy implies strong clinician and patient trust in outcomes and reliability for a critical therapy area.
Brand Trust moat: definition, examples, and stocks
Erosion risks
- Quality or safety events
- Innovation disruption from new voice tech
- Reimbursement changes
Leading indicators
- Laryngectomy growth vs market
- Competitive win/loss in key accounts
- Adverse event/recall frequency
Counterarguments
- Tracheostomy share is much lower, suggesting weaker position in part of the segment
- High share can attract focused competitive entry
Wound & Tissue Repair
Advanced wound dressings and biologics/skin substitutes for wound care
Revenue share computed from H1 2025/26 revenue by business area: Wound & Tissue Repair DKK 1,895m of total DKK 14,127m. H1 organic growth was only 1%, with Kerecis at 0% organic growth and a DKK 3.0bn goodwill impairment.
Insufficient segment-specific evidence to assign a moat claim.
Interventional Urology
Interventional urology products (Kidney & Bladder Health, Men's Health, Women's Health, endourology)
Revenue share computed from H1 2025/26 revenue by business area: Interventional Urology DKK 1,453m of total DKK 14,127m. The latest market-share evidence remains the FY 2024/25 release.
Insufficient segment-specific evidence to assign a moat claim.
Evidence
categories: bags and plates and supporting products.
Defines the main ostomy categories as ongoing-use products, supporting a consumables-driven installed base.
Coloplast is the global market leader with a market share of 35-40%.
Company-stated leadership supports a demand-side brand/trust moat (and scale-related advantages).
Coloplast is the global market leader with a market share of 35-40%.
Used directly as reported share range.
intermittent catheters accounted for around 75% of the continence care market
Highlights that the largest category is intermittent catheters, a high-frequency product category that supports recurring consumption.
Coloplast is the global market leader with a market share of 40-45%.
Company-stated leadership supports a demand-side brand/trust moat (and scale in distribution and clinical education).
Showing 5 of 13 sources.
Risks & Indicators
Erosion risks
- Tender-driven switching
- Reimbursement price pressure
- Competitor product innovation
- Brand damage from quality issues
- Spec/feature parity narrowing differentiation
- Local low-cost competitors in tenders
Leading indicators
- Market share trend
- Price/mix vs volume growth
- Tender win/loss cadence
- Patient satisfaction / complaint rates
- Churn to competitors
- Gross margin in Ostomy category
Research COLOB elsewhere
Keep the research going
More Rankings & Systems
Quality Stocks
High quality stocks ranked by profitability, margins, free cash flow quality, durability, solvency, and accounting...
Stock rankingUndervalued Stocks
Undervalued stocks from the NA & Europe universe, ranked with a multi-measure value system and quality controls.
Stock rankingDividend Stocks
Dividend stocks ranked by payout yield, payout sustainability, dividend growth, quality, balance-sheet safety, risk...
Stock rankingDefensive Stocks
Defensive stocks ranked by low volatility, low beta, intermediate momentum, durable profitability, balance sheet...
Stock rankingMomentum Stocks
Momentum stocks ranked by total return momentum, relative momentum, trend confirmation, and risk-adjusted momentum...
Stock rankingConviction 10
A concentrated 10-stock strategy from the NA & Europe universe, ranked across quality, value, growth, momentum, and...
Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.